Head to Head Comparison: Nyxoah (NASDAQ:NYXH) versus Enovis (NYSE:ENOV)

Nyxoah (NASDAQ:NYXH) and Enovis (NYSE:ENOV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Risk & Volatility

Nyxoah has a beta of 1.56, meaning that its stock price is 56% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.

Profitability

This table compares Nyxoah and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-1,457.97%	-101.99%	-66.74%
Enovis	-52.69%	8.74%	4.19%

Institutional and Insider Ownership

98.5% of Enovis shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by company insiders. Comparatively, 2.7% of Enovis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Nyxoah and Enovis”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$4.89 million	26.05	-$64.10 million	($2.49)	-1.50
Enovis	$2.25 billion	0.62	-$1.18 billion	($20.71)	-1.18

Nyxoah has higher earnings, but lower revenue than Enovis. Nyxoah is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Nyxoah and Enovis, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	1	0	3	1	2.80
Enovis	1	0	7	1	2.89

Nyxoah presently has a consensus target price of $11.67, suggesting a potential upside of 211.94%. Enovis has a consensus target price of $47.43, suggesting a potential upside of 93.67%. Given Nyxoah’s higher possible upside, equities research analysts plainly believe Nyxoah is more favorable than Enovis.

Summary

Enovis beats Nyxoah on 8 of the 14 factors compared between the two stocks.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.